Brief: FDA Removes Partial Clinical Hold On Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial With Seclidemstat In Patients With Ewing Sarcoma

Decoy Therapeutics

09/05/2023 13:48

May 9 (Reuters) - Salarius Pharmaceuticals Inc  SLRX.O :
    * FDA REMOVES PARTIAL CLINICAL HOLD ON SALARIUS
PHARMACEUTICALS’
PHASE 1/2 CLINICAL TRIAL WITH SECLIDEMSTAT IN PATIENTS WITH
EWING SARCOMA
    * FDA REMOVES PARTIAL CLINICAL HOLD ON SALARIUS
PHARMACEUTICALS’
PHASE 1/2 CLINICAL TRIAL WITH SECLIDEMSTAT IN PATIENTS WITH
EWING SARCOMA
    * SALARIUS PHARMACEUTICALS INC - PLANS TO MEET WITH FDA TO
DISCUSS
FUTURE DEVELOPMENT AND POTENTIAL REGISTRATION PATHWAYS

Source text for Eikon:  ID:nGNXbkLC7G 
Further company coverage:  SLRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))